← Back to Screener
GH Research PLC Ordinary Shares (GHRS)
Price$21.43
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)33.43%
Price vs S&P 500 (4W)0.06%
VGM Score71.47
Market Capitalization$1.47B
All Metrics
Book Value / Share (Quarterly)$4.24
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.74
Price vs S&P 500 (YTD)60.58%
EPS (TTM)$-0.91
10-Day Avg Trading Volume0.28M
EPS Excl Extra (TTM)$-0.91
EPS (Annual)$-0.79
ROI (Annual)-17.22%
Cash / Share (Quarterly)$4.31
ROA (Last FY)-16.74%
EBITD / Share (TTM)$-1.07
ROE (5Y Avg)-13.52%
Cash Flow / Share (Annual)$-0.70
P/B Ratio5.58x
P/B Ratio (Quarterly)3.31x
Net Income / Employee (Annual)$-661,100
ROA (TTM)-19.14%
EPS Incl Extra (Annual)$-0.79
Current Ratio (Annual)34.13x
Quick Ratio (Quarterly)23.04x
3-Month Avg Trading Volume0.23M
52-Week Price Return69.94%
Revenue / Employee (TTM)$0
52-Week High$25.94
EPS Excl Extra (Annual)$-0.79
26-Week Price Return41.36%
Quick Ratio (Annual)33.65x
13-Week Price Return41.27%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)23.04x
Enterprise Value$1.23B
Revenue / Employee (Annual)$0
Cash / Share (Annual)$4.53
3-Month Return Std Dev69.65%
Net Income / Employee (TTM)$-772,800
ROE (Last FY)-17.25%
Net Interest Coverage (Annual)-8.48x
EPS Basic Excl Extra (Annual)$-0.79
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.91
ROI (TTM)-19.80%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)45.58%
Year-to-Date Return68.74%
5-Day Price Return-13.69%
EPS Normalized (Annual)$-0.79
ROA (5Y Avg)-13.06%
Month-to-Date Return-10.67%
EBITD / Share (Annual)$-0.99
ROI (5Y Avg)-13.48%
EPS Basic Excl Extra (TTM)$-0.91
P/B Ratio (Annual)2.82x
Book Value / Share (Annual)$4.51
Price vs S&P 500 (13W)33.01%
Beta1.39x
Revenue / Share (TTM)$0.00
ROE (TTM)-19.83%
52-Week Low$11.32
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.31est. -0.28
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.20
4.20
4.20
4.20
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
GHRSGH Research PLC Ordinary Shares | — | — | B | $21.43 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
GH Research PLC is a clinical-stage biopharmaceutical company developing novel mebufotenin-based therapies for treatment-resistant depression. The company's pipeline includes two proprietary candidates: GH001, an inhalable formulation, and GH002, an intravenous formulation. GH Research is focused on addressing a significant unmet medical need in depression treatment through its dedicated R&D operations.